PeDRA 2025Abstract 075
Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis
Results From the OptIMMize-1 Phase 3 Study
Magnolo N, Lee LW, Reich A, Lara-Corrales I, Morita A, Bukhalo M, Vicente A, Anschutz T, Lyles RD, Unnebrink K, Huber C, Ashley DG, Madihlaba T, Patel M, Setty AR, Anschutz T, Paller AS
PeDRA Annual Conference 2025Minneapolis, 9–11 Oct 2025 · published in JID 9 Mar 2026
Topics: PsoriasisPediatric dermatology
Abstract
The abstract’s text is on the JID website.
DOI 10.1016/s0022-202x(26)00610-x · Not in PubMed: details from Crossref